CHA Comments on Stimulant Medication Shortages

Children’s health groups are asking HHS and the DEA to convene stakeholders to identify actionable solutions about ongoing stimulant medication shortages.

Published May 23, 2024 | 1 min. read
Download

Children's Hospital Association and other children’s health groups submitted joint comments to the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) requesting the convening of stakeholders to identify actionable solutions about ongoing stimulant medication shortages.

Our comments highlight the long-term negative impacts that children and their families may experience due to untreated attention deficit hyperactivity disorder and that these shortages exacerbate existing health disparities among families enrolled in Medicaid and CHIP.

Related Content

Pharmacy Technicians Capture 98% of Medication Histories

Specially trained technicians catch errors before they reach patients and remove the burden from nurses.

Sep. 10, 2026

How CHA Mitigated a Cancer Drug Shortage’s Impact

The recent shortage highlighted pediatrics’ vital need for ifosfamide.

Sep. 01, 2026

Why the Pediatric Workforce Crisis Demands Federal Action

A congressional briefing highlighted how workforce shortages are threatening children’s access to care.

July 22, 2026